SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Gynecologic Oncology Consultation — Gwen Ifill

PatientGwen Ifill
Date of birth1965-09-29
IdentifiersMRN HR-ML032-SYN; SSN (made up) 000-32-5814
Document date2026-01-20
AuthorMiriam Delacroix, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Referral

Postmenopausal bleeding for three weeks in a 60-year-old journalist, about eight years after her last period and with no hormone use. An office endometrial biopsy was taken today and a transvaginal ultrasound is booked this week. Please see her within two weeks to review both results with her and plan treatment if they show cancer or atypical hyperplasia. [S]

Urgency: Within two weeks; sooner if the biopsy shows cancer. [S]

Questions for the consultant:

History of Present Illness

Ms. Ifill, 60, is seen at the request of Dr. Achebe-Price two weeks after she first reported three weeks of postmenopausal bleeding. An office endometrial biopsy was taken at that visit, and a transvaginal ultrasound two days later. The biopsy shows endometrioid adenocarcinoma, and CT was done the following week. The bleeding is now occasional spotting; she has no pain, bowel or bladder change, or leg swelling. She takes no hormones. She works long days as a journalist and anchor and wants to keep working through treatment if possible, and to decide who is told. [S]

Historical basis. These claims are historical evidence, not findings from a modern examination.

3 later historical claims are omitted because they describe events after the index age. See the teaching note.

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Problems

ProblemClinical statusVerificationCodeProvenance
Postmenopausal bleeding for three weeks, about eight years after her last period, in a woman of 60 who takes no hormone therapy: endometrial cancer must be excluded. Office endometrial biopsy taken today, transvaginal ultrasound this week, and gynecologic oncology review bookedresolvedconfirmed N95.0S — Synthetic presenting problem; no symptom of her real illness was made public. Superseded by the diagnosis at the gynecologic oncology consultation.
Endometrioid adenocarcinoma of the endometrium, FIGO grade 2, mismatch repair deficient (loss of MLH1 and PMS2 staining), p53 wild-type pattern, on office endometrial biopsy, with enlarged right pelvic and para-aortic lymph nodes on CT; surgical staging planned; synthetic modern detail linked to her publicly reported endometrial canceractiveconfirmed C54.1S — Synthetic histology, molecular result and extent; her family gave endometrial cancer as the cause of death (D), and nothing more about it was made public.

Physical Exam

Vital signs recorded on 2026-01-20; see the referring visit's Vital Signs section. [S]

SystemFinding
GeneralWell; weight 74.2 kg; blood pressure 132/82, pulse 84
AbdomenSoft, non-tender; no mass or fluid
PelvicWith a chaperone: small amount of blood at the cervical os; cervix normal; uterus mobile, slightly enlarged; no adnexal mass or parametrial thickening
Lymph nodesNo inguinal or supraclavicular nodes

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-01-20Hemoglobin [Mass/volume] in Blood12.1g/dL12-15.5 g/dLNormalS
2026-01-20Leukocytes [#/volume] in Blood by Automated count610*3/uL4-11 10*3/uLNormalS
2026-01-20Neutrophils [#/volume] in Blood by Automated count3.610*3/uL1.5-7.7 10*3/uLNormalS
2026-01-20Platelets [#/volume] in Blood by Automated count27410*3/uL150-400 10*3/uLNormalS
2026-01-20Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-01-20Potassium [Moles/volume] in Serum or Plasma4.3mmol/L3.5-5.1 mmol/LNormalS
2026-01-20Creatinine [Mass/volume] in Serum or Plasma0.8mg/dL0.59-1.04 mg/dLNormalS
2026-01-20Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M84mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-01-20Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma19U/L7-35 U/LNormalS
2026-01-20Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma21U/L8-35 U/LNormalS
2026-01-20Bilirubin.total [Mass/volume] in Serum or Plasma0.5mg/dL0.1-1.2 mg/dLNormalS
2026-01-20Albumin [Mass/volume] in Serum or Plasma4.1g/dL3.5-5 g/dLNormalS
2026-01-20Cancer Ag 125 [Units/volume] in Serum or Plasma28U/mL<=35 U/mLNormalS
2026-01-20Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S
2026-01-20Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]7{score}S

Assessment

Data reviewed: Dr. Achebe-Price's intake note. Endometrial biopsy: endometrioid adenocarcinoma, FIGO grade 2; mismatch repair immunohistochemistry with loss of MLH1 and PMS2 and retained MSH2 and MSH6; p53 wild-type pattern. Transvaginal ultrasound: endometrium 16 mm, heterogeneous, with an irregular junction with the myometrium and internal flow; two small intramural fibroids; normal ovaries. CT of the chest, abdomen and pelvis: enlarged uterine cavity; a 1.5 cm right external iliac node and a 1.7 cm left para-aortic node below the renal veins; no liver, lung, bone or peritoneal lesion; no ascites. Today: CA-125 28 U/mL; hemoglobin 12.1 g/dL, platelets 274; creatinine 0.80 mg/dL; albumin 4.1 g/dL. [S]

Plan of Treatment